评论
打印
A UK-listed company backed by Li Ka-shing, one of Asia’s richest men, says it is moving closer to producing the first modern drug developed in China for decades in a sign of the country’s potential to become a force in the pharmaceuticals industry.
由亚洲首富之一李嘉诚(Li Ka-shing)支持、伦敦上市的和黄中国医药科技（Hutchison China MediTech，简称：和黄医药）表示，正接近生产几十年来在中国研发的首款现代药物，这一迹象表明中国有望成为制药领域的一支生力军。
Hutchison China MediTech predicts it will submit its first medicines for regulatory approval next year with several others following behind as the Hong Kong-based company attempts to move beyond traditional Chinese herbal remedies into modern cancer treatments.
和黄医药预测，将于明年将其首批药品提交监管部门审批，之后将提交其他药品审批。这家总部位于香港的公司正试图超越中国传统的中草药疗法，进入现代癌症治疗领域。
Christian Hogg, chief executive, said Chi-Med was aiming to become China’s first large-scale developer of homegrown innovative pharmaceuticals.
和黄医药首席执行官贺隽(Christian Hogg)表示，该公司的目标是成为中国首家本土创新药物的大规模开发者。
“For the past 20 years, China has been a passenger in drug development but that is beginning to change,” Mr Hogg told the Financial Times.
贺隽告诉英国《金融时报》：“过去20年，中国一直是药物开发领域的乘客，但这点正开始发生变化。”
Chi-Med is a subsidiary of Mr Li’s Hutchison Whampoa group and its holding company is listed on London’s junior Aim stock exchange. It has 16 clinical studies under way involving seven experimental medicines for a range of cancers and inflammatory diseases.
和黄医药隶属于李嘉诚旗下的和记黄埔(Hutchison Whampoa)集团，其控股公司在伦敦二板市场——另类投资市场(AIM)上市。该公司目前从事16项临床研究，涉及7种实验药物，针对各种癌症和炎症。
Mr Hogg said the two most promising of these were on track to be filed for regulatory approval in 2016. Fruquintinib, developed in partnership with Eli Lilly of the US, is targeted at colorectal and lung cancer, while savolitinib, co-developed with AstraZeneca of the UK, is aimed at kidney and gastric cancer.
贺隽表示，其中两款最具潜力的药物将在2016年提交监管审批。与美国礼来(Eli Lilly)合作研发的呋喹替尼 (Fruquintinib)用于结肠直肠癌和肺癌的治疗，与英国阿斯利康(AstraZeneca)共同研发的savolitinib旨在治疗肾癌和胃癌。
Analysts cautioned that there was no guarantee of success either in clinical trials or in winning share of the fiercely competitive oncology market if approved. But Savvas Neophytou at Panmure Gordon said the company was making faster-than-expected progress. A big increase in research and development investment revealed last week “could shave off up to a year in development time” for fruquintinib, he added.
分析师们告诫称，如果获得审批，并不能保证该公司会获得临床试验成功，或者在竞争激烈的治癌药物市场成功赢得市场份额。但潘密尔高登(Panmure Gordon)的萨瓦斯•尼奥斐托(Savvas Neophytou)表示，该公司取得的进展快于预期。他补充称，上周公布的研发投资大规模增加，有望将呋喹替尼的“研发时间缩短至多一年”。
